RT Journal Article
SR Electronic
T1 BND-22, a first-in-class humanized ILT2-blocking antibody, promotes antitumor immunity and tumor regression
JF Journal for ImmunoTherapy of Cancer
JO J Immunother Cancer
FD BMJ Publishing Group Ltd
SP e004859
DO 10.1136/jitc-2022-004859
VO 10
IS 9
A1 Mandel, Ilana
A1 Haves Ziv, Dana
A1 Goldshtein, Ilana
A1 Peretz, Tsuri
A1 Alishekevitz, Dror
A1 Fridman Dror, Anna
A1 Hakim, Motti
A1 Hashmueli, Sharon
A1 Friedman, Itay
A1 Sapir, Yair
A1 Greco, Rita
A1 Qu, Hongjing
A1 Nestle, Frank
A1 Wiederschain, Dmitri
A1 Pao, Lily
A1 Sharma, Sharad
A1 Ben Moshe, Tehila
YR 2022
UL http://jitc.bmj.com/content/10/9/e004859.abstract
AB Markup server — Error Not Found The page you were trying to reach could not be found. Please check the address for the page you were trying to reach. If you believe you have reached this page in error, you may contact us with any questions.